Zealand Pharma stock drops 20% as trial shows high discontinuation in weight-loss drug

Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial

Zealand Pharma's stock price declined by approximately 20% following results from a clinical trial showing that a significant portion of participants discontinued use of the company's weight-loss medication. The discontinuation rate among trial users was substantial enough to negatively impact investor confidence in the drug's commercial viability. The trial data suggests potential challenges with user adherence to the weight-loss treatment.